{"filing":{"accession_number":"0001648257-26-000055","cik":"0001648257","ticker":"HMDCF","company_name":"HUTCHMED (China) Ltd","form":"6-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"hcm-20260831x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1648257/000164825726000055/hcm-20260831x6k.htm"},"events":[{"id":30454,"run_id":27912,"accession_number":"0001648257-26-000055","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This announcement discloses positive Phase III trial results for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC in China. The SANOVO trial demonstrated statistically significant progression-free survival benefit and encouraging overall survival results. This is a material clinical development milestone for a co-developed product that extends the therapeutic indication into the first-line setting, representing a significant operational and commercial advancement for the company's pipeline.","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":[{"id":33052,"accession_number":"0001648257-26-000055","item_number":"EX-99.1","item_title":"hcm-20260831xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses positive Phase III trial results for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC in China. The SANOVO trial demonstrated statistically significant progression-free survival benefit and encouraging overall survival results. This is a material clinical development milestone for a co-developed product that extends the therapeutic indication into the first-line setting, representing a significant operational and commercial advancement for the company's pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:00:43.805770+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33052,"accession_number":"0001648257-26-000055","item_number":"EX-99.1","item_title":"hcm-20260831xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses positive Phase III trial results for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC in China. The SANOVO trial demonstrated statistically significant progression-free survival benefit and encouraging overall survival results. This is a material clinical development milestone for a co-developed product that extends the therapeutic indication into the first-line setting, representing a significant operational and commercial advancement for the company's pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:00:43.805770+00:00","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-08-31"}]}